To include your compound in the COVID-19 Resource Center, submit it here.

Metadate MR methylphenidate: Phase III data; NDA under review

CCH subsidiary Medeva Pharmaceuticals Inc. reported data from a 314-patient trial

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE